Rain Oncology Inc

Change company Symbol lookup

Select an option...

RAIN Rain Oncology Inc

MA Mastercard Inc

WDBG Neuro-Hitech Inc

GLRY Inspire Faithward Mid Cap Momentum ETF

WCC Wesco International Inc

TNP-F Tsakos Energy Navigation Ltd

ANEB Anebulo Pharmaceuticals Inc

NCA Nuveen California Municipal Value Fund

SGOL abrdn Physical Gold Shares ETF

GAB-K Gabelli Equity Trust Inc

Go

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.